Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients

Polymyxin B (PMB) has reemerged as a last‐line therapy for infections caused by multidrug‐resistant gram‐negative pathogens, but dosing is challenging because of its narrow therapeutic window and pharmacokinetic (PK) variability. Population PK (POPPK) models based on suitably powered clinical studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanafin, Patrick O., Nation, Roger L., Scheetz, Marc H., Zavascki, Alexandre P., Sandri, Ana M., Kwa, Andrea L., Cherng, Benjamin P. Z., Kubin, Christine J., Yin, Michael T., Wang, Jiping, Li, Jian, Kaye, Keith S., Rao, Gauri G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674003/
https://www.ncbi.nlm.nih.gov/pubmed/34811968
http://dx.doi.org/10.1002/psp4.12720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674003/
https://www.ncbi.nlm.nih.gov/pubmed/34811968
http://dx.doi.org/10.1002/psp4.12720

Ejemplares similares